Benzinga

Benzinga

Benzinga

domingo, agosto 30

Recursion Pharmaceuticals Inc

RXRXNASDAQ
Trade with Public
Trade with Public
$3.34
-0.10-2.91%
al cierre: Aug 28, 5:00 PM EST
$3.35
0.00920.28%
After hour: Aug 28, 7:59 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Recursion Pharmaceuticals Financials

Recursion Pharmaceuticals (RXRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Recursion Pharmaceuticals Q1 EPS $(0.22) Beats $(0.27) Estimate, Sales $6.472M Miss $15.777M Estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.27) by 18.52 percent. This is a 56 percent increase over losses of $(0.50) per share
Benzinga Newsdesk

PRO
Recursion's 2025 Cash Balance Was $753.9M With Expected Cash Runway Extending Into Early 2028

Benzinga Newsdesk

Recursion Pharmaceuticals Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
Recursion Pharmaceuticals Q4 2025 EPS $(0.21) Beats $(0.27) Estimate, Sales $35.537M Beat $24.586M Estimate

Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved